Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Telix Pharmaceuticals Ltd
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-83.1% vs price
Base Case (Median)
-74.3% vs price
Bull Case (75th pct.)
-65.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.14 | -56.7% | High (40%) |
| Earnings Power Value | $0.76 | -92.0% | Medium (50%) |
Based on 2 out of 7 methods, TLX appears overvalued at the current price of $9.54. The base case fair value of $2.45 implies 74.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.